Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates

BACKGROUND: A new promising therapeutic approach has emerged for patients chronically infected by the hepatitis B virus (HBV) with the development of a non-replicative adenovirus vector vaccine candidate (Ad-HBV). The vaccine encodes a fusion protein composed of a truncated HBV core protein, mutated...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xuefeng, Wang, Jing, Lu, Jing, Li, Rongrong, Zhao, Shuli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056916/
https://www.ncbi.nlm.nih.gov/pubmed/30041659
http://dx.doi.org/10.1186/s12985-018-1026-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056916/
https://www.ncbi.nlm.nih.gov/pubmed/30041659
http://dx.doi.org/10.1186/s12985-018-1026-3

Ejemplares similares